GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » COGS-to-Revenue

Ceapro (TSXV:CZO) COGS-to-Revenue : 0.88 (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Ceapro COGS-to-Revenue?

Ceapro's Cost of Goods Sold for the three months ended in Dec. 2023 was C$1.45 Mil. Its Revenue for the three months ended in Dec. 2023 was C$1.65 Mil.

Ceapro's COGS to Revenue for the three months ended in Dec. 2023 was 0.88.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ceapro's Gross Margin % for the three months ended in Dec. 2023 was 12.11%.


Ceapro COGS-to-Revenue Historical Data

The historical data trend for Ceapro's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ceapro COGS-to-Revenue Chart

Ceapro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.50 0.39 0.42 0.59

Ceapro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.54 0.43 0.59 0.88

Ceapro COGS-to-Revenue Calculation

Ceapro's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=5.677 / 9.633
=0.59

Ceapro's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.451 / 1.651
=0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ceapro  (TSXV:CZO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ceapro's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1.451 / 1.651
=12.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Ceapro COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ceapro's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ceapro (TSXV:CZO) Business Description

Traded in Other Exchanges
Address
7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2
Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.

Ceapro (TSXV:CZO) Headlines

No Headlines